Word: paste
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...endowment woes (and resulting budget cuts) have come under constant scrutiny not only by The Crimson, but also by national newspapers such as The Boston Globe and The New York Times. But just in case you’ve been living under a rock for the past few months, FM has gathered some stats on the recession’s effects on Harvard, ranging from the obvious to the surprising to the potentially infuriating. Just remember: regardless of what our endowment is and what our administrators get paid, there is “a wealth of intellectual opportunity within this...
Kevin King, Standish's mayor for the past six years, says most of his constituents want domestic inmates. But accepting detainees from Guantánamo Bay, he says, "is a whole different ball of wax." At community meetings in recent months, King says he has made the point to skeptics that terrorists have long been housed at U.S. prisons, and "you can't recite one terrorist attack by people trying to get out." He says he has received assurances from federal officials that should detainees be brought to Standish, no land near the prison would be seized to expand...
Fast Facts: • A U.S. citizen, Mehanna is the fifth person living in the U.S. to be arrested on terrorism charges in the past five months...
...lawmakers, according to figures compiled by the nonpartisan watchdog group Center for Responsive Politics. The drug industry's legion of registered lobbyists numbers 1,228, or 2.3 for every member of Congress. And its campaign contributions to current members of Waxman's committee have totaled $2.6 million over the past three years. (See 10 players in health-care reform...
...Most small biologics companies are still years away from seeing their first profits in this high-risk, high-return business. Their trade association, BIO, says that in the past 11 months, at least 40 of them have cut back or eliminated drug-development programs. The venture capitalists who invest in them "aren't looking to cure Parkinson's disease as much as they are looking for a return on their investments," says Greenwood. "They're just as happy to put their money into the next iPod." But increasingly, the big players in the pharmaceutical industry are moving into the biologics...